169 related articles for article (PubMed ID: 38765328)
21. Utilization of the Parenteral Morphine in Emergency Department using the Anatomical Therapeutic Chemical Classification/Defined Daily Doses (ATC/DDD) System.
Bozorgi F; Salehifar E; Hosseininejad SM; Moradi S; Janbazi G; Chabra A
Bull Emerg Trauma; 2020 Jul; 8(3):186-192. PubMed ID: 32944579
[TBL] [Abstract][Full Text] [Related]
22. The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial.
Tao R; Chen J; Wang D; Li Y; Xiang J; Xiong L; Ji J; Wu J; Zhou S; Jia C; Lv J; Yang J; Tang Q
Front Endocrinol (Lausanne); 2022; 13():937958. PubMed ID: 35813628
[TBL] [Abstract][Full Text] [Related]
23. Medical treatment of erectile dysfunction: too many medical prescriptions?
Capogrosso P; Ventimiglia E; Oreggia D; Salonia A; Montorsi F
Urologia; 2017 Aug; 84(3):121-129. PubMed ID: 28708203
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterase-5 inhibitors: Shedding new light on the darkness of depression?
Duarte-Silva E; Filho AJMC; Barichello T; Quevedo J; Macedo D; Peixoto C
J Affect Disord; 2020 Mar; 264():138-149. PubMed ID: 32056743
[TBL] [Abstract][Full Text] [Related]
25. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
26. Multiple PDE5Is use as a marker of decreased overall men's health: A real-life study.
Oreggia D; Ventimiglia E; Capogrosso P; Boeri L; Cazzaniga W; Pederzoli F; Chierigo F; Dehò F; Montorsi F; Salonia A
PLoS One; 2018; 13(8):e0201601. PubMed ID: 30096166
[TBL] [Abstract][Full Text] [Related]
27. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis.
Abbasi B; Shaw NM; Lui JL; Hakam N; Nabavizadeh B; Breyer BN
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5721. PubMed ID: 37909414
[TBL] [Abstract][Full Text] [Related]
28. National Consumption of Antimicrobials in Tanzania: 2017-2019.
Mbwasi R; Mapunjo S; Wittenauer R; Valimba R; Msovela K; Werth BJ; Khea AM; Nkiligi EA; Lusaya E; Stergachis A; Konduri N
Front Pharmacol; 2020; 11():585553. PubMed ID: 33192526
[No Abstract] [Full Text] [Related]
29. Non-invasive alternative for phosphodiesterase inhibitor-refractory erectile dysfunction: Real-life experience with low-intensity extracorporeal shockwave therapy.
Bayraktar N
Medicine (Baltimore); 2023 Nov; 102(45):e35939. PubMed ID: 37960801
[TBL] [Abstract][Full Text] [Related]
30. Distribution and trends in outpatient utilization of generic versus brand name psychopharmaceuticals during a ten-year period in Croatia.
Polić-ViŽintin M; Stimac D; Sostar Z; Tripković I
BMC Health Serv Res; 2014 Aug; 14():343. PubMed ID: 25128190
[TBL] [Abstract][Full Text] [Related]
31. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.
Evans JD; Hill SR
Patient Prefer Adherence; 2015; 9():1159-64. PubMed ID: 26316720
[TBL] [Abstract][Full Text] [Related]
33. Analysis of prescriptions of alpha-blockers and phosphodiesterase 5 inhibitors from the urology department and other departments.
Kang DH; Lee JY; Chung JH; Cho HJ; Cho JM; Moon HS; Kim YT; Yoo TK; Choi HY; Park HY; Lee SW
Int Neurourol J; 2011 Dec; 15(4):216-21. PubMed ID: 22259736
[TBL] [Abstract][Full Text] [Related]
34. The Treatment Satisfaction in Patients and Their Partners Treated with Low-Intensity Extracorporeal Shock Wave Therapy and Sildenafil: A Prospective Non-Randomized Controlled Study.
Wang D; Wang SJ; Li YJ; Liu CH; Li YQ; Zhang YS; Yan S
Patient Prefer Adherence; 2023; 17():583-589. PubMed ID: 36919185
[TBL] [Abstract][Full Text] [Related]
35. Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events.
Belladelli F; Li S; Zhang CA; Muncey W; Del Giudice F; Glover F; Seranio N; Basran S; Fallara G; Montorsi F; Salonia A; Eisenberg ML
J Sex Med; 2023 Nov; 20(12):1399-1406. PubMed ID: 37861186
[TBL] [Abstract][Full Text] [Related]
36. P144, A TGF-β1 antagonist peptide, synergizes with sildenafil and enhances erectile response via amelioration of cavernosal fibrosis in diabetic rats.
Li WJ; Wang H; Zhou J; Li B; Zhang J; Lu M; Wang Z
J Sex Med; 2013 Dec; 10(12):2942-51. PubMed ID: 24134744
[TBL] [Abstract][Full Text] [Related]
37. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
38. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.
Cho MC; Paick JS
Ther Adv Urol; 2016 Apr; 8(2):100-17. PubMed ID: 27034723
[TBL] [Abstract][Full Text] [Related]
39. Study of the prevalence and patterns of phosphodiesterase type 5 inhibitor use among sexually active Egyptian males: A National Cross-sectional Survey.
Attia AA; Abdel-Hameed AKS; Amer MAEM; Mamdouh H; GamalEl Din SF; El-Moslemany HEGM
Andrologia; 2019 Oct; 51(9):e13364. PubMed ID: 31304987
[TBL] [Abstract][Full Text] [Related]
40. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors.
Schnetzler G; Banks I; Kirby M; Zou KH; Symonds T
J Sex Med; 2010 Mar; 7(3):1237-46. PubMed ID: 20136707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
